Infection and Drug Resistance (Sep 2024)
Mupirocin for Skin Infection: Clinical Experience from China
Abstract
Jing Sun,1 Tracy Lu,1 Yan Dang,1 Zigang Xu,2 Ying Liu2 1Medical & Scientific Affairs, Haleon (Formerly GSK Consumer Healthcare), Shanghai, People’s Republic of China; 2Department of Dermatology, Beijing Children’s Hospital, Capital Medical University, National Key Discipline of Pediatrics, Key Laboratory of Major Diseases in Children, Ministry of Education, National Center for Children‘s Health, Beijing, People’s Republic of ChinaCorrespondence: Ying Liu, Department of Dermatology, Beijing Children’s Hospital, Capital Medical University, National Key Discipline of Pediatrics, Key Laboratory of Major Diseases in Children, Ministry of Education, National Center for Children’s Health, Beijing, People’s Republic of China, Email [email protected]: Mupirocin, an antibiotic produced by Pseudomonas fluorescens, is mainly used for the topical treatment of various skin and soft tissue infections caused by Staphylococcus (including methicillin-resistant Staphylococcus aureus) and Streptococcus around the world for decades. Nevertheless, the clinical application scope of mupirocin varies in different countries due to differences in their medical policies, prescription types, and drug resistance. According to the experience of Chinese doctors in the past few years, mupirocin presented low drug resistance rates, and could be used as a treatment option for various primary infections and secondary infections, with antibacterial effects in a broad application. In this review, we summarized the experience of mupirocin used in the Chinese population and discussed its clinical value to provide novel insights and inspiration for physicians.Keywords: experience, mupirocin, skin diseases, infectious
